Catalyst Pharmaceuticals Inc.

14.05-0.1600-1.13%Vol 1.06M1Y Perf -12.66%
Nov 29th, 2023 16:00 DELAYED
BID13.91 ASK14.45
Open14.29 Previous Close14.21
Pre-Market- After-Market13.98
 - -  -0.07 -0.50%
Target Price
19.90 
Analyst Rating
Strong Buy 1.40
Potential %
41.64 
Finscreener Ranking
★★★★+     56.15
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★★★★+     58.44
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★★★★     84.66
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
26.86 
Earnings Rating
Sell
Market Cap1.50B 
Earnings Date
8th Nov 2023
Alpha0.03 Standard Deviation0.19
Beta1.08 

Today's Price Range

14.0314.45

52W Range

11.0922.11

5 Year PE Ratio Range

-8.8018.20

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Strong Buy
Performance
1 Week
1.37%
1 Month
15.16%
3 Months
-2.70%
6 Months
21.65%
1 Year
-12.66%
3 Years
283.88%
5 Years
453.15%
10 Years
716.86%

TickerPriceChg.Chg.%
CPRX14.05-0.1600-1.13
AAPL189.37-1.0300-0.54
GOOG136.40-2.2200-1.60
MSFT378.85-3.8500-1.01
XOM102.34-1.5600-1.50
WFC43.780.41000.95
JNJ152.110.48000.32
FB196.640.99000.51
GE118.860.01000.01
JPM154.320.78000.51
Financial StrengthValueIndustryS&P 500US Markets
5.90
6.20
0.01
0.01
-
Leverage Ratio 1.20
ProfitabilityValueIndustryS&P 500US Markets
84.10
43.70
44.00
-
37.54
RevenueValueIndustryS&P 500US Markets
153.45M
1.47
79.99
-
Earnings HistoryEstimateReportedSurprise %
Q02 20230.250.3332.00
Q01 20230.300.26-13.33
Q04 20220.210.224.76
Q03 20220.190.205.26
Q02 20220.170.2017.65
Q01 20220.140.12-14.29
Q04 20210.120.09-25.00
Q03 20210.100.100.00
Earnings Per EndEstimateRevision %Trend
12/2023 QR0.44-6.38Negative
12/2023 FY1.43-12.80Negative
3/2024 QR0.462.22Positive
12/2024 FY2.132.90Positive
Next Report Date-
Estimated EPS Next Report-0.24
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume1.06M
Shares Outstanding106.61K
Shares Float87.53M
Trades Count11.43K
Dollar Volume15.03M
Avg. Volume919.09K
Avg. Weekly Volume615.16K
Avg. Monthly Volume1.01M
Avg. Quarterly Volume1.13M

Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX) stock closed at 14.05 per share at the end of the most recent trading day (a -1.13% change compared to the prior day closing price) with a volume of 1.06M shares and market capitalization of 1.50B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 76 people. Catalyst Pharmaceuticals Inc. CEO is Patrick J. McEnany.

The one-year performance of Catalyst Pharmaceuticals Inc. stock is -12.66%, while year-to-date (YTD) performance is -24.46%. CPRX stock has a five-year performance of 453.15%. Its 52-week range is between 11.09 and 22.11, which gives CPRX stock a 52-week price range ratio of 26.86%

Catalyst Pharmaceuticals Inc. currently has a PE ratio of 32.10, a price-to-book (PB) ratio of 7.55, a price-to-sale (PS) ratio of 12.90, a price to cashflow ratio of 22.70, a PEG ratio of -, a ROA of 25.63%, a ROC of 28.06% and a ROE of 30.53%. The company’s profit margin is 37.54%, its EBITDA margin is 44.00%, and its revenue ttm is $153.45 Million , which makes it $1.47 revenue per share.

Of the last four earnings reports from Catalyst Pharmaceuticals Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.24 for the next earnings report. Catalyst Pharmaceuticals Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Catalyst Pharmaceuticals Inc. is Strong Buy (1.4), with a target price of $19.9, which is +41.64% compared to the current price. The earnings rating for Catalyst Pharmaceuticals Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Catalyst Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Catalyst Pharmaceuticals Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 15.28, ATR14 : 0.52, CCI20 : 104.68, Chaikin Money Flow : 0.08, MACD : 0.36, Money Flow Index : 77.66, ROC : 14.04, RSI : 60.88, STOCH (14,3) : 81.65, STOCH RSI : 0.42, UO : 52.98, Williams %R : -18.35), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Catalyst Pharmaceuticals Inc. in the last 12-months were: Alicia Grande (Option Excercise at a value of $135 500), Alicia Grande (Sold 110 000 shares of value $1 822 313 ), Brian Elsbernd (Option Excercise at a value of $56 500), Brian Elsbernd (Sold 50 000 shares of value $803 450 ), Carmen Jeffrey Del (Sold 0 shares of value $-127 063 ), Carmen Jeffrey Del (Sold 40 000 shares of value $667 810 ), Charles B. O'Keeffe (Option Excercise at a value of $79 000), David S. Tierney (Option Excercise at a value of $39 500), David S. Tierney (Sold 30 000 shares of value $504 900 ), Denkhaus Donald (Sold 0 shares of value $-107 300 ), Donald A. Denkhaus (Option Excercise at a value of $39 500), Elsbernd Brian (Sold 0 shares of value $-56 500 ), Elsbernd Brian (Sold 50 000 shares of value $803 500 ), Gary Ingenito (Option Excercise at a value of $0), Gary Ingenito (Sold 5 918 shares of value $99 718 ), Grande Alicia (Option Excercise at a value of $135 500), Grande Alicia (Sold 110 000 shares of value $1 822 313 ), Harper Molly (Option Excercise at a value of $0), Ingenito Gary (Option Excercise at a value of $0), Molly Harper (Option Excercise at a value of $0), Patrick J. McEnany (Option Excercise at a value of $158 000), Patrick J. Mcenany (Sold 26 151 shares of value $345 978 ), Philip H. Coelho (Option Excercise at a value of $0), Preethi Sundaram (Option Excercise at a value of $0), Richard J. Daly (Option Excercise at a value of $0), Steve Miller (Sold 0 shares of value $-79 000 ), Steven R. Miller (Option Excercise at a value of $0), Sundaram Preethi (Option Excercise at a value of $0)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
4 (80.00 %)
4 (80.00 %)
4 (80.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
1 (20.00 %)
1 (20.00 %)
1 (20.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.40
Strong Buy
1.40
Strong Buy
1.40

Catalyst Pharmaceuticals Inc.

Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing innovative therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with lambert-eaton myasthenic syndrome.

CEO: Patrick J. McEnany

Telephone: +1 305 420-3200

Address: 355 Alhambra Circle, Coral Gables 33134, FL, US

Number of employees: 76

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

52%48%

Bearish Bullish

57%43%

Bearish Bullish

53%47%

 

TipRanks News for CPRX

Mon, 14 Aug 2023 12:48 GMT Catalyst Pharmaceuticals announces multiple abstracts on FYCOMPA

- TipRanks. All rights reserved.

News

Stocktwits